Similar to how mTOR inhibitors have risen to efficacy against sarcoidosis, the identification of these molecular dysregulations facilitates the future use of drugs inhibiting these pathways, leading to a reduction in granulomatous inflammation and progression of the disease. Here, MTOR is linked to sarcoidosis.